Krishnan Hajela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Krishnan Hajela has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Alexander G. Obukhov
Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine
5 shared publications Uzma Saqib
5 shared publications- Asgar Ali
Bihar Technical Support Program , Patna, Bihar
4 shared publications Komal Choudhary
Department of School of Life Sciences, Devi Ahilya Vishwavidyalaya, Indore, Madhya Pradesh, India
3 shared publicationsKshitij Gupta
School of Life Sciences, DA University, Indore, India
3 shared publicationsMonika Pandey
3 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by Impact Journals, LLC in Oncotarget
- Vol. 17 (1) , 54-56
CAR-T therapy: Trailblazing CAR(ing) in cancer treatment
- 6 January 2026
- Published by Impact Journals, LLC in Oncotarget
- Vol. 17 (1) , 54-56
Open AccessCAR-T therapy: Trailblazing CAR(ing) in cancer treatment
- Open Access
Lipoxins as Modulators of Diseases
Lipoxins were discovered 40 years ago, and since then, their beneficial roles for human health have been confirmed in numerous studies. These small molecules belong to the eicosanoid class of compounds, which are generated metabolically by lipoxygenases. Lipoxins are released during various diseases and conditions, including but not limited to systemic inflammation, infection, asthma, cancer, diabetes, and cardiovascular disorders. Recently, several synthetic lipoxin analogs have been developed that also exhibit potent anti-inflammatory properties. In this review, we discuss the inflammation-resolving roles of lipoxins in various major diseases. Further, we summarize the latest reports on the use of synthetic lipoxins as potential therapeutic agents and discuss the role of aspirin-dependent lipoxin production in alleviating various diseases, including cancer.
Open AccessLipoxins as Modulators of Diseases
Lipoxins were discovered 40 years ago, and since then, their beneficial roles for human health have been confirmed in numerous studies. These small molecules belong to the eicosanoid class of compounds, which are generated metabolically by lipoxygenases. Lipoxins are released during various diseases and conditions, including but not limited to systemic inflammation, infection, asthma, cancer, diabetes, and cardiovascular disorders. Recently, several synthetic lipoxin analogs have been developed that also exhibit potent anti-inflammatory properties. In this review, we discuss the inflammation-resolving roles of lipoxins in various major diseases. Further, we summarize the latest reports on the use of synthetic lipoxins as potential therapeutic agents and discuss the role of aspirin-dependent lipoxin production in alleviating various diseases, including cancer.
- Open Access
- 20 January 2025
- Published by Impact Journals, LLC in Oncotarget
- Vol. 16 (1) , 133-135
EXPOSOMES and GENES: The duo influencing CANCER initiation and progression
- 20 January 2025
- Published by Impact Journals, LLC in Oncotarget
- Vol. 16 (1) , 133-135
Open AccessEXPOSOMES and GENES: The duo influencing CANCER initiation and progression
- 3 January 2025
- Published by Springer Nature in Catalysis Letters
- Vol. 155 (2) , 1-13
Biochemical Characterization and Wash Performance Analysis of a Protease Purified from the Seeds of Cyamopsis tetragonoloba
- 3 January 2025
- Published by Springer Nature in Catalysis Letters
- Vol. 155 (2) , 1-13
Biochemical Characterization and Wash Performance Analysis of a Protease Purified from the Seeds of Cyamopsis tetragonoloba
- Open Access
- 1 April 2024
- Published by Lepidus Tecnologia in Brazilian Journal of Science
- Vol. 3 (5) , 1-18
Purification and characterization of lipase from a new strain Staphylococcus argenteus MG2 (MTCC 12820)
The lipase enzyme was isolated and purified from Staphylococcus argenteus MG2 (MTCC 12820) to homogeneity using ammonium sulphate precipitation followed by chromatographic techniques. This process resulted in a purification factor of 40.96-fold and a 26.25% recovery with a specific activity of 744.68 U mg-1. The molecular weight of the purified lipase was determined by SDS-PAGE to be 45 kDa. The Km and Vmax values of the purified lipase were calculated to be 4.95 mM and 79.36 µmol/min/mg-1, respectively. The maximum lipase activity was observed at pH 7.0 and 30 ºC with 100% stability, and it was also found to be stable in a broad range of pH (5-12) and temperature (30-90 ºC). The enzymatic activity of this Staphylococcal lipase was increased by Ca2+ to 105.71% at a concentration of 1 mM CaCl2. Additionally, it exhibited marked stability and activity in organic solvents. In the presence of 1% SDS surfactant, it retained 85.16% residual activity, while the metal chelator EDTA (inhibitor) reduced the lipase activity to 83.87% residual activity at a concentration of 1% w/v. This alkali-stable and thermo-stable lipase can be exploited by extending its use in the preparation of detergents and in various industrial and biotechnological applications.
- 1 April 2024
- Published by Lepidus Tecnologia in Brazilian Journal of Science
- Vol. 3 (5) , 1-18
Open AccessPurification and characterization of lipase from a new strain Staphylococcus argenteus MG2 (MTCC 12820)
The lipase enzyme was isolated and purified from Staphylococcus argenteus MG2 (MTCC 12820) to homogeneity using ammonium sulphate precipitation followed by chromatographic techniques. This process resulted in a purification factor of 40.96-fold and a 26.25% recovery with a specific activity of 744.68 U mg-1. The molecular weight of the purified lipase was determined by SDS-PAGE to be 45 kDa. The Km and Vmax values of the purified lipase were calculated to be 4.95 mM and 79.36 µmol/min/mg-1, respectively. The maximum lipase activity was observed at pH 7.0 and 30 ºC with 100% stability, and it was also found to be stable in a broad range of pH (5-12) and temperature (30-90 ºC). The enzymatic activity of this Staphylococcal lipase was increased by Ca2+ to 105.71% at a concentration of 1 mM CaCl2. Additionally, it exhibited marked stability and activity in organic solvents. In the presence of 1% SDS surfactant, it retained 85.16% residual activity, while the metal chelator EDTA (inhibitor) reduced the lipase activity to 83.87% residual activity at a concentration of 1% w/v. This alkali-stable and thermo-stable lipase can be exploited by extending its use in the preparation of detergents and in various industrial and biotechnological applications.
- 27 January 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (9) , 4729-4742
Structural and accessibility studies highlight the differential binding of clemizole to TRPC5 and TRPC6
Transient Receptor Potential Canonical 5 (T RP C5) and T RP C6 channels play critical physiological roles in various cell types. Their involvement in numerous disease progression mechanisms has led to extensive searches for their inhibitors. Although several potent T RP C inhibitors have been developed and the structure of their binding sites were mapped using cryo electron microscopy, a comprehensive understanding of the molecular interactions within the inhibitor binding site of T RP Cs remains elusive. This study aimed to decipher the structural determinants and molecular mechanisms contributing to the differential binding of clemizole to T RP C5 and T RP C6, with a particular focus on the accessibility of binding site residues. This information can help better understand what molecular features allow for selective binding, which is a key characteristic of clinically effective pharmacological agents. Using computational methodologies, we conducted an in-depth molecular docking analysis of clemizole with T RP C5 and T RP C6 channels. The protein structures were retrieved from publicly accessible protein databases. Discovery Studio 2020 Client Visualizer and Chimera software facilitated our in-silico mutation experiments and enabled us to identify the critical structural elements influencing clemizole binding. Our study reveals key molecular determinants at the clemizole binding site, specifically outlining the role of residues' Accessible Surface Area (ASA) and Relative Accessible Surface Area (RASA) in differential binding. We found that lower accessibility of T RP C6 binding site residues, compared to those in T RP C5, could account for the lower affinity binding of clemizole to T RP C6. This work illuminates the pivotal role of binding site residue accessibility in determining the affinity of clemizole to T RP C5 and T RP C6. A nuanced understanding of the distinct binding properties between these homologous proteins may pave the way for the development of more selective inhibitors, promising improved therapeutic efficacy and fewer off-target effects. By demystifying the structural and molecular subtleties of T RP C inhibitors, this research could significantly accelerate the drug discovery process, offering hope to patients afflicted with T RP C-related diseases.
- 27 January 2024
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (9) , 4729-4742
Structural and accessibility studies highlight the differential binding of clemizole to TRPC5 and TRPC6
Transient Receptor Potential Canonical 5 (T RP C5) and T RP C6 channels play critical physiological roles in various cell types. Their involvement in numerous disease progression mechanisms has led to extensive searches for their inhibitors. Although several potent T RP C inhibitors have been developed and the structure of their binding sites were mapped using cryo electron microscopy, a comprehensive understanding of the molecular interactions within the inhibitor binding site of T RP Cs remains elusive. This study aimed to decipher the structural determinants and molecular mechanisms contributing to the differential binding of clemizole to T RP C5 and T RP C6, with a particular focus on the accessibility of binding site residues. This information can help better understand what molecular features allow for selective binding, which is a key characteristic of clinically effective pharmacological agents. Using computational methodologies, we conducted an in-depth molecular docking analysis of clemizole with T RP C5 and T RP C6 channels. The protein structures were retrieved from publicly accessible protein databases. Discovery Studio 2020 Client Visualizer and Chimera software facilitated our in-silico mutation experiments and enabled us to identify the critical structural elements influencing clemizole binding. Our study reveals key molecular determinants at the clemizole binding site, specifically outlining the role of residues' Accessible Surface Area (ASA) and Relative Accessible Surface Area (RASA) in differential binding. We found that lower accessibility of T RP C6 binding site residues, compared to those in T RP C5, could account for the lower affinity binding of clemizole to T RP C6. This work illuminates the pivotal role of binding site residue accessibility in determining the affinity of clemizole to T RP C5 and T RP C6. A nuanced understanding of the distinct binding properties between these homologous proteins may pave the way for the development of more selective inhibitors, promising improved therapeutic efficacy and fewer off-target effects. By demystifying the structural and molecular subtleties of T RP C inhibitors, this research could significantly accelerate the drug discovery process, offering hope to patients afflicted with T RP C-related diseases.
- Open Access
- 6 January 2024
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 31-34
The fate of drug discovery in academia; dumping in the publication landfill?
- 6 January 2024
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 31-34
Open AccessThe fate of drug discovery in academia; dumping in the publication landfill?
- Open Access
- 1 September 2023
- Published by Scientific Scholar in Journal of Health Science Research
- Vol. 8 (2) , 38-44
Variations in antioxidant status in ischemic stroke: A case control study in Indian population
Objectives: An imbalance between the levels of oxidants and antioxidants, a state of oxidative stress, leads to production of Reactive Oxygen Species. Overproduction of these species plays a crucial role in pathogenesis of ischemic stroke. In view of this, we aimed to investigate the markers of oxidative stress along with blood cellular components in ischemic stroke patients and healthy controls. Material and Methods: Blood samples of 68 patients and 52 aged-matched controls were analyzed for oxidative stress markers such as glutathione peroxidase (GSHPx) and reduced glutathione (GSH) were assayed along with catalase and superoxide dismutase (SOD). Ferric-reducing antioxidant power (FRAP) of plasma of all samples was also evaluated along with complete blood count. Results: In patients, the activities of the oxidative stress marker enzyme, GSHPx, was found to be significantly elevated (P ≤ 0.01), with significantly low levels of GSH (P ≤ 0.01), while the activities of catalase and SOD were found unaltered. The total antioxidant capacity of plasma measured as FRAP was also significantly higher (P ≤ 0.05). Red blood cells (RBCs) and eosinophils counts were found to be significantly lower (P ≤ 0.05 and P ≤ 0.01, respectively) while that of monocytes were significantly higher (P ≤ 0.01) in comparison with the controls. Conclusion: Our results showed that the antioxidant status of ischemic stroke patients was better than the control subjects, which may have been due to the compensatory mechanism being activated due to oxidative stress.
- 1 September 2023
- Published by Scientific Scholar in Journal of Health Science Research
- Vol. 8 (2) , 38-44
Open AccessVariations in antioxidant status in ischemic stroke: A case control study in Indian population
Objectives: An imbalance between the levels of oxidants and antioxidants, a state of oxidative stress, leads to production of Reactive Oxygen Species. Overproduction of these species plays a crucial role in pathogenesis of ischemic stroke. In view of this, we aimed to investigate the markers of oxidative stress along with blood cellular components in ischemic stroke patients and healthy controls. Material and Methods: Blood samples of 68 patients and 52 aged-matched controls were analyzed for oxidative stress markers such as glutathione peroxidase (GSHPx) and reduced glutathione (GSH) were assayed along with catalase and superoxide dismutase (SOD). Ferric-reducing antioxidant power (FRAP) of plasma of all samples was also evaluated along with complete blood count. Results: In patients, the activities of the oxidative stress marker enzyme, GSHPx, was found to be significantly elevated (P ≤ 0.01), with significantly low levels of GSH (P ≤ 0.01), while the activities of catalase and SOD were found unaltered. The total antioxidant capacity of plasma measured as FRAP was also significantly higher (P ≤ 0.05). Red blood cells (RBCs) and eosinophils counts were found to be significantly lower (P ≤ 0.05 and P ≤ 0.01, respectively) while that of monocytes were significantly higher (P ≤ 0.01) in comparison with the controls. Conclusion: Our results showed that the antioxidant status of ischemic stroke patients was better than the control subjects, which may have been due to the compensatory mechanism being activated due to oxidative stress.
- 18 April 2023
- Published by Springer Nature in Inflammation
- Vol. 46 (4) , 1144-1160
Transient Receptor Potential Canonical 6 (TRPC6) Channel in the Pathogenesis of Diseases: A Jack of Many Trades
The mammalian Transient Receptor Potential Canonical (TRPC) subfamily comprises seven transmembrane proteins (TRPC1–7) forming cation channels in the plasma membrane of mammalian cells. TRPC channels mediate Ca2+ and Na+ influx into the cells. Amongst TRPCs, TRPC6 deficiency or increased activity due to gain-of-function mutations has been associated with a multitude of diseases, such as kidney disease, pulmonary disease, and neurological disease. Indeed, the TRPC6 protein is expressed in various organs and is involved in diverse signalling pathways. The last decade saw a surge in the investigative studies concerning the physiological roles of TRPC6 and describing the development of new pharmacological tools modulating TRPC6 activity. The current review summarizes the progress achieved in those investigations.
- 18 April 2023
- Published by Springer Nature in Inflammation
- Vol. 46 (4) , 1144-1160
Transient Receptor Potential Canonical 6 (TRPC6) Channel in the Pathogenesis of Diseases: A Jack of Many Trades
The mammalian Transient Receptor Potential Canonical (TRPC) subfamily comprises seven transmembrane proteins (TRPC1–7) forming cation channels in the plasma membrane of mammalian cells. TRPC channels mediate Ca2+ and Na+ influx into the cells. Amongst TRPCs, TRPC6 deficiency or increased activity due to gain-of-function mutations has been associated with a multitude of diseases, such as kidney disease, pulmonary disease, and neurological disease. Indeed, the TRPC6 protein is expressed in various organs and is involved in diverse signalling pathways. The last decade saw a surge in the investigative studies concerning the physiological roles of TRPC6 and describing the development of new pharmacological tools modulating TRPC6 activity. The current review summarizes the progress achieved in those investigations.
- Open Access
- 29 March 2023
- Published by Springer Nature in Research Square
Differential binding of Clemizole among TRPC homologs
The Transient Receptor Potential Canonical (TRPC) channels play important physiological roles and are involved in various signalling events in many organs. Amongst TRPC channels, the TRPC6 channel is one of the most studied, due to its involvement in multiple mechanisms of disease progression. Although several inhibitors of TRPC channels have been discovered, none of them have progressed to clinical trials. Clemizole is a potent TRPC5 antagonist with low affinity to TRPC6. In this study, we investigated the structural determinants and molecular aspects of TRPC5 and TRPC6 interaction with clemizole. We identified the critical clemizole binding site molecular determinants as well as the residues’ Accessible Surface Area (ASA) and Relative Accessible Surface Area (RASA) values. These results may facilitate drug discovery process.
- 29 March 2023
- Published by Springer Nature in Research Square
Open AccessDifferential binding of Clemizole among TRPC homologs
The Transient Receptor Potential Canonical (TRPC) channels play important physiological roles and are involved in various signalling events in many organs. Amongst TRPC channels, the TRPC6 channel is one of the most studied, due to its involvement in multiple mechanisms of disease progression. Although several inhibitors of TRPC channels have been discovered, none of them have progressed to clinical trials. Clemizole is a potent TRPC5 antagonist with low affinity to TRPC6. In this study, we investigated the structural determinants and molecular aspects of TRPC5 and TRPC6 interaction with clemizole. We identified the critical clemizole binding site molecular determinants as well as the residues’ Accessible Surface Area (ASA) and Relative Accessible Surface Area (RASA) values. These results may facilitate drug discovery process.